XPO Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? XPO Inc. Common Stock trades at $183.47 (market cap $21.30B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: XPO Inc. Common Stock is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while XPO Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold XPO Inc. Common Stock for 1 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| XPO | ZBH | |
|---|---|---|
Market Cap | $21.30B | $16.95B |
Volume | 897,705 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $228.37 | $103.98 |
52-Week Low | $123.66 | $79.58 |
Typical Hold Time | 1 Days | 89 Days |
Enterprise Value | $24.99B | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Trailing returns across standard periods
Latest headlines on both assets
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →